Article
Spatial-Immune Multi-omics Refines Prognostication in Early-Stage Estrogen Receptor-Positive Breast Cancer
2025-10-12
Abstract excerpt
<title>Abstract</title> <p> Despite a strong 5–10 year prognosis, in ER <sup>+</sup> HER2 <sup>−</sup> breast cancer relapses are common beyond 10 years. Genomic assays employed to determine recurrence risk at diagnosis are still ambiguous for a significant proportion of patients with Intermediate risk (i.e. Oncotype Dx Recurrence Score (RS) 16–25). We demonstrate that macrophage and T-helper cells facilitat...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- c0cabfd7-ed2a-5d85-9449-0f00f60b8164
- DOI
- 10.21203/rs.3.rs-7726652/v1
